← Back

BIIBBiogen

$213.68-3.24%Real quote · delayedBiopharma

🏛️ Company factsSEC filings + FINRA official data

Annual revenue $9.9B · latest quarter up 1.9% YoY · profitable (FY net income $1.3B) · short activity above its recent average — bears adding.

FY revenue

$9.9B

2025-12

Latest Q YoY

+1.9%

Gross margin

17.6%

FY net income

$1.3B

Diluted EPS

$8.83

Short volume

66.7%

20d avg 60.4% · shorts building

🐋 5%+ ownership filings (last 180d)

The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.

2026-08-06passive (13G)FMR LLC
2026-04-29passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
2026-03-26passive (13G)VANGUARD GROUP INC

🎯 Market expectations

Expectation reliability Medium · 46/100

Nasdaq analyst consensus · the pre-news baseline

Next quarter (Sep 2026) consensus$2.31Estimate range $1.71 ~ $4.25 · 10 analysts

History: actual vs consensusavg +21.7%

Jun 2026$3.60 vs $3.04+18.42%
Mar 2026$3.57 vs $2.95+21.02%
Dec 2025$1.99 vs $1.61+23.6%
Sep 2025$4.81 vs $3.89+23.65%

The takeaway

This company habitually beats by +21.7% — the next report has to clear that bar to count as good news.

Analyst estimates, not our forecast · not investment advice

🧭 -3.2% today with no fresh news · why?

📊 Market-0.1%S&P -0.4% × beta 0.2
💸 Money flowMFI 49 · net inflow · volume 0.5× average
🧩 PeersFBRX 0%RHHBY -1.5%LLY -2.3%IONS -3.1%DYN -14.7%MRNA -2.6%5 peers moved the same way today, averaging -4% — this is a sector move, not a single-stock event.
🕰️ Old news, still digesting▲ FDA Approves First Drug to Treat Alexander Diseastructural impact active, ~55 days left

Educational decomposition · not investment advice

What's moving this stock lately

0 direct · 1 2nd-order · 0 thematic

Ranked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)

#1▲0.92%2nd-orderFDA Approves First Drug to Treat Alexander Disease5d ago
As Ionis's longtime ASO partner (e.g., Spinraza), the approval indirectly reinforces confidence in the platform's commercial viability for future joint pipeline programs
Impact chain →
Also named: IONS · SRPT

🕰️ Price × news · engine report card

Drag to pan, scroll to zoom · real daily bars and volume

The 2 engine calls on this chart (hit / miss / pending) are Pro — price and volume only for now▂ volume

📜 Call history (newest first

🔒 Pro only

2 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view

🔒 Pro only

Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.